• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

BIOPHARMA CREDIT PLC

Notes

No. Proposition For Against Abstain
1

TO RECEIVE AND, IF THOUGHT FIT, TO ADOPT THE STRATEGIC REPORT, DIRECTORS REPORT, AUDITORS REPORT AND THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

2

TO RECEIVE AND APPROVE THE DIRECTORS REMUNERATION REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

3

TO ELECT NIGEL REYNOLDS AS A DIRECTOR OF THE COMPANY

4

TO RE-ELECT HARRY HYMAN AS A DIRECTOR OF THE COMPANY

5

TO RE-ELECT STEPHANIE LEOUZON AS A DIRECTOR OF THE COMPANY

6

TO RE-ELECT SAPNA SHAH AS A DIRECTOR OF THE COMPANY

7

TO RE-ELECT ROLF SODERSTROM AS A DIRECTOR OF THE COMPANY

8

TO RE-APPOINT ERNST AND YOUNG LLP AS AUDITOR TO THE COMPANY, TO HOLD OFFICE UNTIL THE CONCLUSION OF THE NEXT GENERAL MEETING

9

TO AUTHORISE THE DIRECTORS TO DETERMINE THE REMUNERATION OF THE AUDITOR OF THE COMPANY

10

TO APPROVE THE COMPANYS DIVIDEND POLICY

11

PURSUANT TO ARTICLE 104, TO INCREASE THE LIMIT ON THE AGGREGATE REMUNERATION PAYABLE TO THE DIRECTORS TO AN ANNUAL SUM OF USD 850,000

12

THAT THE DIRECTORS BE AUTHORISED TO ALLOT SHARES IN THE COMPANY AND TO GRANT RIGHTS TO SUBSCRIBE FOR, OR TO CONVERT ANY SECURITY INTO, SHARES

13

THAT SUBJECT TO RESOLUTION 12, THE DIRECTORS BE AUTHORISED TO ALLOT EQUITY SECURITIES FOR CASH AS IF SECTION 561 OF THE ACT DID NOT APPLY

14

THAT THE COMPANY BE AND IS HEREBY GENERALLY AND UNCONDITIONALLY AUTHORISED TO MAKE MARKET PURCHASES OF ORDINARY SHARES OF USD 0.01 EACH

15

THAT A GENERAL MEETING, OTHER THAN AN ANNUAL GENERAL MEETING, MAY BE CALLED ON NOT LESS THAN 14 CLEAR DAYS NOTICE